ArticleCancer science2007
Reduced transthyretin expression in sera of lung cancer.
Article in Cancer science, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Evaluation of the Potential Diagnostic Utility of the Determination of Selected Immunological and Molecular Parameters in Patients with Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- New Predictive Biomarkers for Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2021Review
- Identification of potential cervical cancer serum biomarkers in Thai patients.Oncology letters · 2020Article
- Epigallocatechin‑3‑gallate modulates long non‑coding RNA and mRNA expression profiles in lung cancer cells.Molecular medicine reports · 2019Article
- High preoperative serum prealbumin predicts long-term survival in resected esophageal squamous cell cancer.Cancer management and research · 2019Article
- Review
- CD5 molecule-like and transthyretin as putative biomarkers of chronic myeloid leukemia - an insight from the proteomic analysis of human plasma.Scientific reports · 2017Article
- Marketed drugs used for the management of hypercholesterolemia as anticancer armament.OncoTargets and therapy · 2017Review
- Selective expression of transthyretin in subtypes of lung cancer.Journal of molecular histology · 2016Article
- Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Transthyretin as a potential biomarker for the differential diagnosis between lung cancer and lung infection.Biomedical reports · 2014Article
- Proteomic biomarkers in lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2013Review
- Serum biomarkers identification by mass spectrometry in high-mortality tumors.International journal of proteomics · 2013Article
- Changes of transthyretin and clusterin after androgen ablation therapy and correlation with prostate cancer malignancy.Translational oncology · 2012Article
- A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2012Article
- Potential biomarkers in the sera of breast cancer patients from bahawalpur, pakistan.Biomarkers in cancer · 2012Article
- Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease?Molecular neurodegeneration · 2011Review
- Article
- Proteomic analysis of chronic restraint stress-induced Gan (肝)-stagnancy syndrome in rats.Chinese journal of integrative medicine · 2010Article
- Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q).Leukemia · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is a leading cause of cancer death worldwide, and very few specific biomarkers can be used in its clinical diagnosis. Using surface-enhanced laser desorption-ionization time-of-flight mass spectrometry (MS) to find novel serum biomarkers for lung cancer, we analyzed 227 serum samples, including 146 lung cancers, 41 benign lung diseases and 40 normal individuals. Three peaks, at 13.78, 13.90 and 14.07 k m/z, were significantly lower in lung cancer sera compared with sera from normal individuals (P < 0.001), whereas these peaks were higher than those in the sera of benign lung diseases (P < 0.001). The peaks were identified as native transthyretin (TTR) and its two variants by one-dimensional polyacrylamide gel electrophoresis, ESI-MS/MS, immunoprecipitation and western blot analysis. An enzyme-linked immunosorbent assay indicated that TTR levels were consistent with surface-enhanced laser desorption-ionization analysis in all groups tested. It gave 78.5% sensitivity and 77.5% specificity for lung cancer versus normal at the cut-off point 115 microg/mL, and 66.7% sensitivity and 64.4% specificity for lung cancer versus benign lung diseases at the cut-off point 88.5 microg/mL. Therefore, TTR may be useful as a biomarker to improve the diagnosis of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.